[ad_1]
The Bloomberg news agency reported that Sweden’s astrazeneca and the University of Oxford have published the results of the phase III trial of the AZD1222 vaccine, a vaccine against the COVID-19 virus. The final step is that the AZD1222 vaccine is 70% effective against COVID-19, which is 60% above the threshold but still lower than the Pfizer vaccine. That was 97% protected and 94.5% lower than the Modena vaccine.
AstraZeneca said it has been testing two different vaccines. In the second trial with 9,000 volunteers, the vaccine had a protective efficacy of 62% and the average rate reached 90%. Level above 70%
AstraZeneca confirmed that there were no serious events during the trial. Not including anyone infected with the Critical COVID-19 virus AND no volunteers were sent to the hospital in any way.
However, even the Astra Seneca vaccine. It will have less protective efficacy than Pfizer and Modena, but the AstraZeneca vaccine. It can be stored in a normal refrigerator. This is different from the vaccines from the other two companies that only need to be stored in special low-temperature refrigerators. That it is easy to transport and suitable for middle-income countries.
AstraZeneca had to stop conducting vaccine trials in September after a volunteer fell ill for unknown reasons. There is also news that a volunteer has died after participating in an experiment with the company last month. Subdistrict in the past
